Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025

Ongoing Phase 1b/2 Trial of the Allosteric MEK1/2 Inhibitor REC-4881 as Monotherapy (FAP): Updated Safety and Efficacy Najat Khan, Ph.D ., Chief R&D and Chief Commercial Officer and incoming CEO and ...
GEN - Genetic Engineering and Biotechnology News

Recursion’s Incoming CEO on Turning AI Drugs Into Clinical Proof Points

Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.
How-To Geek on MSN

The surprising reason JavaScript is the best language for beginners

For many reasons, including those I’ve already covered, JavaScript is a very popular programming language. In fact, according ...